📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Aster DM Q4FY26 Combined Revenue Up 18% to ₹2,361 Cr; Merger with QCIL Nears Completion
Aster DM Healthcare reported strong proforma combined results for Q4FY26, with revenue growing 18% YoY to ₹2,361 crore and EBITDA rising 25% to ₹517 crore. The company's operational efficiency improved significantly, with EBITDA margins expanding to 21.9% and RoCE reaching 21.1%. The merger with Quality Care (QCIL) is on track for completion in Q1 FY27, having received 96.68% shareholder approval. Looking ahead, the company plans to expand its bed capacity by 4,445 beds to reach a total of 15,068 beds by FY30.
Key Highlights
Combined proforma revenue for Q4FY26 grew 18% YoY to ₹2,361 crore, while FY26 revenue reached ₹9,273 crore.
Operating EBITDA for the combined entity increased 25% YoY to ₹517 crore in Q4, with margins improving by 118 bps to 21.9%.
Total patient volumes rose 12% YoY to 1.93 million, supported by a 210 bps increase in occupancy to 61%.
The merger with Quality Care (QCIL) is expected to conclude in Q1 FY27, creating a massive healthcare platform with a pipeline to reach 15,068 beds.
Standalone India business (Aster) saw a 32% YoY growth in normalized PAT to ₹140 crore for the quarter.
💼 Action for Investors
Investors should view the strong margin expansion and the imminent merger with QCIL as significant value drivers. The aggressive bed expansion plan provides a clear long-term growth trajectory for the combined entity.
Loading analysis...
Aster DM Q4 FY26: Revenue up 18% to ₹1,182 Cr; EBITDA (ex-Kasargod) jumps 31%
Aster DM Healthcare reported a robust Q4 FY26 with revenue growing 18% YoY to INR 1,182 Cr and normalized PAT (ex-Kasargod) surging 45% to INR 153 Cr. Operating EBITDA margins (ex-Kasargod) improved significantly to 21.7% from 19.3% in the previous year, driven by operating leverage and disciplined cost management. The merger with Quality Care India Ltd (QCIL) is on track for completion in Q1 FY27, having received 96.68% shareholder approval. On a proforma basis, the combined entity's revenue reached INR 2,361 Cr with a healthy EBITDA margin of 21.9%.
Key Highlights
Revenue for Q4 FY26 grew 18% YoY to INR 1,182 Cr; Operating EBITDA (ex-Kasaragod) rose 31% to INR 253 Cr.
Normalised PAT (ex-Kasaragod) witnessed a robust 45% YoY growth, reaching INR 153 Cr.
Average Revenue Per Occupied Bed (ARPP) for IP rose 9% YoY to INR 1,25,234, with total patient volumes up 15%.
Medical Value Travel (MVT) revenue grew by 41% YoY, led by a 51% surge in Kerala MVT revenue.
Merger with QCIL is expected to close in Q1 FY27, creating a platform with over 10,623 beds across 28 cities.
💼 Action for Investors
Investors should note the strong margin expansion and the significant growth in Medical Value Travel as positive indicators of operational efficiency. The upcoming merger with QCIL is a major catalyst that will scale the company into one of India's top three healthcare providers.
Loading analysis...
Aster DM Healthcare Board Approves FY26 Audited Results; Auditors Issue Unmodified Opinion
Aster DM Healthcare's Board of Directors approved the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. Statutory auditors Deloitte Haskins & Sells issued an unmodified opinion, confirming the financial statements present a true and fair view of the company's performance. The results incorporate the DM Healthcare Employees Welfare Trust, which reported total assets of INR 19.57 crores. This announcement confirms the completion of the annual audit process without any reported accounting discrepancies.
Key Highlights
Board approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors Deloitte Haskins & Sells issued an unmodified audit opinion for the full financial year.
The DM Healthcare Employees Welfare Trust (ESOP Trust) reported total assets of INR 19.57 crores before eliminations.
The board meeting was conducted over a five-hour session, concluding at 3:35 PM IST on April 30, 2026.
💼 Action for Investors
Investors should review the detailed profit and loss statements and balance sheet once the full tables are released to assess operational margins. The unmodified audit opinion is a positive indicator of the company's financial reporting integrity.
Loading analysis...
Aster DM Completes 26% Stake Acquisition in Oyster Green Hybrid for Revised INR 5.80 Cr
Aster DM Healthcare and its subsidiary MIMS have finalized the acquisition of a 26% stake in Oyster Green Hybrid Two Private Limited. The total consideration was revised downward to INR 5.80 crore from the initial INR 7 crore due to a reduction in overall project costs. This acquisition is a strategic move to fulfill statutory requirements for a captive 18 MWp solar power plant in Kerala, which will supply 100% of its net output to the group's facilities. The final tranche of INR 2.26 crore was completed on April 22, 2026, marking the formal conclusion of the deal.
Key Highlights
Acquisition of 26% equity stake in Oyster Green Hybrid Two Private Limited completed.
Total investment revised to INR 5.80 crore from the earlier estimate of INR 7 crore.
The deal enables access to an 18 MWp captive solar power plant project in Kerala.
Final payment tranche of INR 2.26 crore executed on April 22, 2026.
Move aimed at meeting electricity requirements through renewable energy sources and reducing long-term costs.
💼 Action for Investors
This is a positive step towards operational efficiency and ESG compliance through renewable energy adoption. While the transaction size is small, it reflects disciplined capital allocation by reducing the acquisition cost in line with project expenses.
Loading analysis...
Aster DM Shareholders Approve Dr. Azad Moopen's Appointment; Section 185 Resolution Narrowly Passes
Aster DM Healthcare's shareholders have approved the appointment of Dr. Mandayapurath Azad Moopen as Executive Director with 99.84% support. A second special resolution regarding the granting of loans and guarantees under Section 185 also passed, but with a much narrower margin of 75.57%. Notably, institutional investors showed strong resistance to the loan resolution, with 64.22% of their votes cast against it. This suggests a significant divide between the promoter group and institutional shareholders regarding corporate lending and guarantee practices.
Key Highlights
Dr. Azad Moopen's appointment as Executive Director received 47.40 crore votes in favour (99.84%).
Section 185 resolution for loans and guarantees passed with 75.57% favour, just clearing the 75% special resolution hurdle.
Institutional investors cast 11.60 crore votes (64.22% of their category) against the Section 185 resolution.
Promoter group voted 100% in favour of both resolutions, representing 21.76 crore shares.
Total of 47.48 crore valid votes were polled for the loan resolution out of 1.39 lakh eligible shareholders.
💼 Action for Investors
While leadership remains stable, investors should exercise caution and monitor the company's future inter-corporate loan activities given the high level of institutional dissent. The narrow passing of the Section 185 resolution indicates that institutional shareholders may have concerns regarding capital allocation.
Loading analysis...
Aster DM Expands Whitefield Hospital Capacity to 539 Beds with Rs 96 Cr Investment
Aster DM Healthcare has invested Rs 96 crore to expand its specialized 'Women & Children' facility at Aster Whitefield Hospital in Bengaluru. This expansion adds 159 beds, increasing the total capacity of the Whitefield unit from 380 to 539 beds. The move is part of a larger regional strategy to reach 2,573 beds in Karnataka, including upcoming projects in Yeshwantpur and Sarjapur. The facility focuses on high-margin specialized services such as Level 3A NICU, fetal medicine, and fertility treatments.
Key Highlights
Investment of Rs 96 crore to add a dedicated 159-bed specialized facility
Aster Whitefield's total bed capacity increased from 380 to 539 beds
Total Karnataka bed capacity to reach 2,573 beds with upcoming Yeshwantpur and Sarjapur facilities
Facility features advanced services including Level 3A NICU, water birthing, and fetal surgery
Aster DM currently operates 20 hospitals with 5,451 beds across India
💼 Action for Investors
Investors should monitor the ramp-up in occupancy for the new beds as it will drive revenue growth in the high-margin mother and child segment. The expansion reinforces Aster's focus on the Indian market following its recent GCC business divestment.
Loading analysis...
Aster DM Healthcare Announces Rs 3 Interim Dividend; Sets April 3, 2026 as Record Date
Aster DM Healthcare has declared an interim dividend of Rs 3 per equity share for the financial year 2025-26. The company has fixed April 3, 2026, as the record date to determine shareholder eligibility for the payout. Tax will be deducted at source (TDS) at a rate of 10% for resident shareholders with a valid PAN for dividends exceeding Rs 10,000. Shareholders must submit relevant tax exemption documents or DTAA declarations by the deadline of April 6, 2026.
Key Highlights
Interim dividend declared at Rs 3 per equity share for the financial year 2025-26.
Record date for dividend entitlement is fixed as April 3, 2026.
Standard TDS rate of 10% applies to resident shareholders with valid PAN for dividends above Rs 10,000.
A higher TDS rate of 20% will be applied if PAN is invalid or not linked with Aadhaar.
Deadline for submitting tax-related documents and declarations is April 6, 2026.
💼 Action for Investors
Investors should ensure their PAN is linked with Aadhaar and bank account details are updated with their Depository Participant to receive the dividend. Eligible shareholders should submit tax exemption forms like Form 121 or DTAA documents before April 6 to avoid higher tax withholding.
Loading analysis...
Aster DM Healthcare Declares Rs 3 Interim Dividend; Record Date April 3, 2026
Aster DM Healthcare has declared an interim dividend of Rs 3 per equity share for the financial year 2025-26, representing 30% of the face value of Rs 10. The Board has fixed April 3, 2026, as the record date to determine eligible shareholders. The dividend payment will be processed within 30 days from the declaration date of March 26, 2026. Shareholders are required to submit tax-related documents by April 6, 2026, to ensure appropriate TDS rates are applied.
Key Highlights
Interim dividend of Rs 3 per equity share for FY 2025-26
Record date for dividend entitlement set for April 3, 2026
Dividend payment to be completed within 30 days of declaration
Deadline for submitting TDS-related documents is April 6, 2026
💼 Action for Investors
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date. Existing shareholders should submit necessary tax documents by April 6 to avoid higher TDS.
Loading analysis...
Aster DM Healthcare Declares Interim Dividend of Rs. 3 Per Share for FY 2025-26
Aster DM Healthcare's Board of Directors has declared an interim dividend of Rs. 3 per equity share for the financial year 2025-26. The dividend is based on a face value of Rs. 10 per share. The company has established April 3, 2026, as the record date to identify eligible shareholders for this payout. The dividend will be paid within 30 days of declaration, after accounting for applicable Tax Deducted at Source (TDS).
Key Highlights
Interim dividend of Rs. 3 per equity share declared for the financial year 2025-26.
Record date for determining shareholder eligibility is fixed as April 3, 2026.
Dividend payment will be processed within 30 days from the date of declaration.
The dividend is subject to TDS as per the provisions of the Income Tax Act, 1961.
💼 Action for Investors
Investors interested in the dividend should ensure they own the stock before the record date of April 3, 2026. This payout reflects the company's commitment to returning value to shareholders.
Loading analysis...
Aster DM Reports ₹17.69 Cr Revenue Loss Due to Kerala Nurse Strike; High Court Intervenes
Aster DM Healthcare has reported a revenue loss of ₹17.69 crore between March 8 and March 13, 2026, due to a statewide nurse strike in Kerala affecting seven of its hospitals. The Kerala High Court has intervened, directing the United Nurses Association to defer the strike until March 19 and move to mediation for wage negotiations. The company anticipates a further potential loss of ₹5.33 crore if the situation resolves by the court-mandated deadline. Management has activated contingency plans, including mobilizing staff from Karnataka, to maintain critical services.
Key Highlights
Reported revenue loss of ₹17.69 crore from March 8 to March 13, 2026
Estimated additional loss of up to ₹5.33 crore expected until March 19
Kerala High Court ordered a temporary halt to the strike and referred the dispute to mediation
Strike affected seven major hospitals including Aster Medcity and MIMS units in Kerala
Company mobilized nursing staff from neighboring Karnataka to ensure continuity of critical care
💼 Action for Investors
Investors should monitor the mediation outcome on March 19, as a permanent wage hike could impact long-term margins in the Kerala cluster. The current financial impact is manageable but highlights labor risks in a core operating region.
Loading analysis...
Aster DM Seeks Approval for Dr. Azad Moopen's Appointment & INR 1,500 Cr Loan Limit
Aster DM Healthcare has issued a postal ballot notice seeking shareholder approval for the appointment of Dr. Mandayapurath Azad Moopen as Executive Director from April 2026 to May 2028. The proposed annual remuneration is capped at INR 10 Crores, which may be paid even in the event of inadequate profits. Furthermore, the company is seeking a mandate to provide loans, guarantees, or securities up to INR 1,500 Crores to its subsidiaries and group entities. This financial limit is intended to support the growth of its core hospital, pharmacy, and diagnostic business segments over the next three years.
Key Highlights
Proposed appointment of Dr. Mandayapurath Azad Moopen as Executive Director for the period April 15, 2026, to May 28, 2028.
Annual remuneration for the Executive Director capped at INR 10 Crores, including fixed salary and variable pay.
Seeking shareholder approval for a loan and guarantee limit of up to INR 1,500 Crores for group entities under Section 185.
The INR 1,500 Crore limit will be valid for three years and restricted to core healthcare business activities.
Remote e-voting period is scheduled from March 14, 2026, to April 12, 2026, with results by April 14.
💼 Action for Investors
Investors should monitor the voting results and subsequent deployment of the INR 1,500 Crore loan limit to ensure capital is used for high-return healthcare expansions. The continuation of the founder's leadership provides stability, though the high remuneration cap during potential profit lean periods should be noted.
Loading analysis...
Aster DM Shareholders Approve Merger with Quality Care India with 96.68% Majority
Aster DM Healthcare has received a decisive 96.68% shareholder approval for its proposed merger with Quality Care India Limited (QCIL). The combined entity, to be named Aster DM Quality Care Ltd, will emerge as one of India's top three hospital chains with a massive capacity of over 10,625 beds. The transaction has already secured CCI and Stock Exchange clearances and is expected to be fully completed in the next quarter following final NCLT approvals. This merger, backed by Blackstone, significantly scales the company's operations to 39 hospitals across 9 states.
Key Highlights
96.68% of shareholders and a significant majority of creditors voted in favor of the merger scheme.
The combined entity will operate 39 hospitals with 10,625+ beds across 9 states and 28 cities.
Merger is on track for completion in the next quarter, pending final statutory NCLT approvals.
The transaction creates one of India's top three hospital chains, supported by Blackstone's institutional expertise.
The combined workforce will exceed 36,307 employees and clinicians serving millions of patients annually.
💼 Action for Investors
Investors should view this as a major positive milestone that significantly enhances the company's market share and scale. Monitor the final NCLT approval and the subsequent integration for potential operational synergies and margin improvements.
Loading analysis...
Aster DM Shareholders Approve Amalgamation with Quality Care India with 96.68% Majority
Shareholders of Aster DM Healthcare have officially approved the Scheme of Amalgamation with Quality Care India Limited (QCIL) in an NCLT-convened meeting held on March 10, 2026. The resolution saw high participation with 93% of outstanding shares being polled. A significant majority of 96.68% of total votes were cast in favor of the merger, satisfying the requirements of both the Companies Act and SEBI regulations. This approval marks a major milestone in the company's structural consolidation process.
Key Highlights
Total votes polled reached 48.18 crore, representing 93.00% of the total outstanding shares.
The merger resolution was approved by 96.68% of the total votes cast.
Public institutional shareholders supported the move with 92.76% of their votes in favor.
Public non-institutional shareholders showed near-unanimous support with 99.99% voting in favor.
The scheme involves the merger of Quality Care India Limited (Transferor) into Aster DM Healthcare (Transferee).
💼 Action for Investors
Investors should view this overwhelming shareholder approval as a positive step toward the company's growth and consolidation strategy. Monitor the final NCLT sanction and subsequent integration updates for long-term value creation.
Loading analysis...
Aster DM Appoints Founder Dr. Azad Moopen as Executive Director until May 2028
The Board of Aster DM Healthcare has approved the appointment of its founder, Dr. Azad Moopen, as an Executive Director effective from April 15, 2026, through May 28, 2028. This role is a redesignation from his current position as Managing Director, though he will continue to serve as the Chairman of the Company. The appointment is subject to shareholder approval via a postal ballot. This move is intended to ensure leadership continuity and leverage Dr. Moopen's decades of institutional knowledge and operational expertise.
Key Highlights
Dr. Azad Moopen appointed as Executive Director for a term from April 15, 2026, to May 28, 2028
Redesignated from Managing Director while retaining his position as Chairman of the Board
Appointment requires final approval from shareholders through a postal ballot process
Dr. Moopen has been associated with the company since its establishment in 1987
Leadership team includes family members Ms. Alisha Moopen (Deputy MD) and Dr. Zeba Azad Moopen (Non-Executive Director)
💼 Action for Investors
Investors should view this as a positive step for leadership stability and continuity of the company's strategic vision. No immediate action is required as the founder remains at the helm of the organization.
Loading analysis...
Aster DM Healthcare Holds Creditors Meeting for Merger with Quality Care India
Aster DM Healthcare convened a meeting of its unsecured trade creditors on March 10, 2026, to seek approval for the Scheme of Amalgamation with Quality Care India Limited. The meeting was held via video conferencing as directed by the NCLT Hyderabad bench, with 51 creditors in attendance. Remote e-voting was conducted between March 6 and March 9, 2026, to facilitate the approval process. The company is now awaiting the final scrutinizer's report to disclose the voting results to the exchanges.
Key Highlights
Meeting of unsecured trade creditors held on March 10, 2026, regarding the merger with Quality Care India Limited.
A total of 51 unsecured trade creditors participated in the NCLT-convened proceedings.
Remote e-voting was active from March 6, 2026 (9:00 AM) to March 9, 2026 (5:00 PM).
The amalgamation scheme is part of a strategic consolidation between the Transferor and Transferee companies.
💼 Action for Investors
Investors should watch for the official voting results to confirm creditor approval, which is a critical milestone for the merger. Successful amalgamation is expected to bring operational synergies and scale to Aster DM's healthcare portfolio.
Loading analysis...
Aster DM Shareholders Meet to Approve Merger with Quality Care India Limited
Aster DM Healthcare held an NCLT-convened meeting on March 10, 2026, to seek shareholder approval for the amalgamation of Quality Care India Limited into the company. The meeting was attended by 64 members via video conferencing and was chaired by an NCLT-appointed advocate. Management addressed shareholder queries regarding the rationale and salient features of the proposed scheme. The final voting results, including remote e-voting conducted between March 6-9, 2026, will be disclosed within the prescribed regulatory timelines.
Key Highlights
NCLT-convened meeting held on March 10, 2026, to approve the Scheme of Amalgamation with Quality Care India Limited.
Remote e-voting period concluded on March 9, 2026, at 5:00 P.M. IST prior to the general meeting.
A total of 64 members participated in the meeting through Video Conferencing and Other Audio Visual Means.
The scheme involves Quality Care India Limited as the Transferor Company and Aster DM Healthcare as the Transferee Company.
Final voting results and the Scrutinizer's report are expected to be disseminated to BSE and NSE shortly.
💼 Action for Investors
Investors should watch for the official voting results to confirm shareholder approval of the merger. Successful amalgamation is expected to consolidate operations and potentially enhance long-term value.
Loading analysis...
Aster DM Merger with Quality Care to Create Top 3 Hospital Chain; 10-15% EBITDA Synergy Expected
Aster DM Healthcare is advancing its merger with Quality Care India Limited to create one of India's top three hospital chains. The combined entity will operate across 9 states and 25 cities, serving approximately 2.0 million patients per quarter. Management expects the merger to generate an EBITDA upside of 10-15% through operational synergies. To address governance concerns, promoters have committed to waiving board nomination rights if their shareholding drops below 10%.
Key Highlights
Merger creates a top 3 Indian hospital chain with 6,690+ clinicians and presence in 25 cities.
Identified synergies expected to provide an EBITDA upside potential of 10-15% of FY24 pro-forma EBITDA.
Shareholders previously approved the preceding Share Swap with an overwhelming 99.998% majority.
Promoters (Aster and Blackstone) committed to governance reforms, including waiving committee nomination rights.
Final equity shareholder meeting for scheme approval scheduled for March 10, 2026.
💼 Action for Investors
Investors should view this as a major growth catalyst that significantly scales the company's footprint and margin profile. Monitor the final voting results from the March 10 meeting to confirm the merger's progression.
Loading analysis...
Aster DM Signs SHA for Sarjapur Subsidiary to Facilitate Fundraising via CCPS
Aster DM Healthcare has entered into a Shareholders' Agreement (SHA) with its wholly-owned subsidiary, Aster DM Super-specialty Hospital (Sarjapur) Private Limited. The agreement is a strategic step to facilitate the subsidiary's plan to raise capital from external investors through Compulsorily Convertible Preference Shares (CCPS). The SHA ensures Aster DM retains significant governance control, including board nomination rights and a call option on shares held by future minority investors. This move indicates a focused expansion strategy for the Sarjapur facility using external capital.
Key Highlights
Aster DM Healthcare signed a Shareholders' Agreement with its Sarjapur subsidiary on February 26, 2026.
The Sarjapur entity intends to raise funds from potential investors through the issuance of Compulsorily Convertible Preference Shares (CCPS).
Aster DM retains the right to nominate directors and holds a call option on shares held by other future shareholders.
The agreement includes strict share transfer restrictions and lock-in periods for potential external investors.
The transaction is conducted at arm's length and does not currently constitute a related party transaction under SEBI regulations.
💼 Action for Investors
Investors should view this as a positive step toward capital-efficient expansion of the Sarjapur facility. Monitor for future announcements regarding the specific amount raised and the identity of the incoming investors to gauge valuation benchmarks.
Loading analysis...
Aster DM Q3 FY26: Combined Revenue up 15% to ₹2,366 Cr; QCIL Merger on Track for Q1 FY27
Aster DM reported a 15% YoY growth in combined proforma revenue to ₹2,366 crore for Q3 FY26, with operating EBITDA rising 22% to ₹503 crore. The merger with Quality Care India Limited (QCIL) is progressing well, with NCLT approval expected by Q1 FY27, which will create a platform with over 14,710 beds. Standalone revenue grew 13% to ₹1,186 crore, supported by a 9% increase in inpatient ARPP and strong growth in Oncology and Medical Value Travel. The company maintained a healthy combined ROCE of 21% while continuing aggressive expansion plans.
Key Highlights
Combined proforma revenue grew 15% YoY to ₹2,366 crore with a 21% EBITDA margin.
Aster standalone revenue increased 13% to ₹1,186 crore, while Oncology revenue surged 27% YoY.
The merger with QCIL is on track for Q1 FY27 completion, following CCI and stock exchange approvals.
Total combined bed capacity reached 10,620+ with a pipeline to add 4,000+ more beds.
Medical Value Travel (MVT) segment grew 41% YoY, driven by a 64% increase in international footfall in Kerala.
💼 Action for Investors
Investors should monitor the upcoming shareholder meeting in late February for the QCIL merger approval, as the combined entity shows superior margins and ROCE. The stock remains a strong play on hospital consolidation and specialty mix improvement in the Indian healthcare sector.
Loading analysis...
Aster DM to Merge with Quality Care to Create India's Top 3 Hospital Chain with 10,625+ Beds
Aster DM Healthcare has announced a major merger with Blackstone-backed Quality Care India Limited (QCIL) to create a healthcare powerhouse with over 10,625 beds. The combined entity, to be named Aster DM Quality Care Limited, reported a proforma 9MFY26 revenue of INR 6,913 Cr and an Operating EBITDA of INR 1,496 Cr with a 21.6% margin. The transaction values Aster at 36.6x FY24 Adj. EBITDA, representing a 45% premium over the multiple ascribed to QCIL. The merger is expected to be EPS accretive from the first full year of operations and will be jointly controlled by Aster promoters and Blackstone.
Key Highlights
Merged entity will have 10,625+ capacity beds across 9 states and 28 cities, operating under brands like Aster, CARE Hospitals, and KIMSHEALTH.
Combined 9MFY26 financial performance shows a healthy Operating EBITDA margin of 21.6% and a RoCE of 20.7%.
Aster DM standalone 9MFY26 revenue grew to INR 3,461 Cr with ARPOB increasing to INR 51,100 from INR 44,200 YoY.
Post-merger shareholding structure will be Aster Promoters (24%), Blackstone (30.7%), and Public/Others (45.3%).
The transaction is cash-neutral and involves a share swap ratio of 977 Aster shares for every 1,000 QCIL shares.
💼 Action for Investors
Investors should view this as a transformative growth milestone that significantly enhances Aster's market position and geographical footprint. The institutional backing from Blackstone and the expected EPS accretion make this a strong long-term play in the Indian healthcare sector.